NCT05758103View on ClinicalTrials.gov

Limosilactobacillus Reuteri as an Adjuvant in the Treatment of Peri-implant Mucositis

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

May 31, 2022

Study Completion Date

September 18, 2022

Conditions
Peri-implant Mucositis
Interventions
DIETARY_SUPPLEMENT

Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)

Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)

Trial Locations (1)

1600-042

Malo Clinic, Lisbon

Sponsors

Lead Sponsor

Malo Clinic
All Listed Sponsors
lead

Malo Clinic

OTHER

NCT05758103 - Limosilactobacillus Reuteri as an Adjuvant in the Treatment of Peri-implant Mucositis | Biotech Hunter | Biotech Hunter